Remove Antibody Remove Genetic Engineering Remove In-Vitro Remove Medicine
article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. This continues to be the standard of care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RNA Therapeutics: A Novel Approach to Treating Diseases

Roots Analysis

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. It is important to highlight that IVT mRNAs are structurally similar to natural mRNAs and can be used to express proteins through genetic engineering.

RNA 40
article thumbnail

How mice with humanised immune systems are advancing cell-based immunotherapy

Drug Discovery World

To mitigate these risks, clinicians are turning to other immunomodulators, such as cell-based therapies, bispecific antibodies, and cytokine treatments. Immune checkpoint inhibitors (ICIs) like pembrolizumab (Keytruda) have numerous benefits and have become a standard of treatment for many patients. Jespersen et al.

In-Vivo 52